• Archer has completed a key step in integrating the Biochip into an at-home potassium monitor prototype
• Archer's graphene field effect transistor (gFET) sensors have been integrated with readout circuitry on a silicon chip
• This integrated chip provides rapid control and reading of many gFET devices

Archer Materials Limited (ASX: AXE), a semiconductor company advancing quantum technology and medical diagnostics, has manufactured its first chip that combines the company's graphene field effect transistor (gFET) sensors with electrical readout circuitry. This is an important milestone for the integration of the Biochip into an at-home testing device for chronic kidney disease. The chips were fabricated at Archer's foundry partner VTT Technical Research Centre of Finland Ltd via a multi-project wafer run on a 200mm wafer. The integrated chip provides rapid control and reading of many gFET devices, which is a key step in packaging the Biochip into a cartridge system suitable for receiving blood samples and being interfaced with a handheld reader. Archer plans to use this first integrated Biochip as part of the Hylid Diagnostics joint development project to begin developing the first version of test cartridges. The company will continue to work on the Biochip development and integration activities, targeting early prototypes and demonstration of initial potassium testing accuracy performance in early 2026.

Archer plans to verify the operation of these new integrated chips in Sydney. The design of these integrated chips will feed into the development work with Hylid Diagnostics to begin integrating the Biochip sensor with homolysis sensors and cartridge designs to house the sensors, and interface with fluidics and a hand-held reader.